Physician profile
Raymond Thomas
NPI 1770500365
$1,740.05
in general payments reported to CMS, 2019-2025
14 companies · $293 in 2025
The $293 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $226 · 2021: $309 · 2022: $194 · 2023: $320 · 2024: $293 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $897 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $897.31 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $448.63 | 2019-2024 | Rybelsus, Ozempic |
| Abbvie INC. | $362.19 | 2021-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $309.20 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Organogenesis INC. | $147.89 | 2023-2025 | Puraply, Via Matrix, Puraply Wound Matrix |
| Smith+Nephew, INC. | $137.41 | 2020-2025 | Grafix Pl |
| Eisai INC. | $86.56 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $60.85 | 2020-2021 | |
| Amgen INC. | $47.60 | 2022-2024 | Repatha, Otezla |
| Paratek Pharmaceuticals, INC. | $46.26 | 2025 | Nuzyra |
| Pfizer INC. | $23.88 | 2020 | |
| Allergan, INC. | $19.36 | 2020 | |
| Integra Lifesciences Corporation | $18.09 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $16.44 | 2025 | Rexulti |
| Astellas Pharma US INC | $15.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.